Sex differences observed in several diseases prompted a new National Institutes of Health (NIH) policy starting in 2016 whereby grant submissions can no longer ignore the possible effect of being female or male. 1 What will happen when all NIH investigators include sex as a biologic variable in their research? Significant effects of sex hormones on diseases will be found. But, will sex hormone treatment candidates be tested in phase 3 trials for regulatory approval in diseases such as multiple sclerosis (MS) where this is so costly? Sex hormone treatments are naturally occurring biologics without product patents. Even when they carry method-of-use patents, hormone treatments on the market for decades for other indications are often available at very low cost. This limits how expensive an approved sex hormone treatment for MS could ultimately be, thereby discouraging large investments into phase 3 trials necessary for their regulatory approval. A bottleneck of sex hormone treatment candidates will likely occur at the stage prior to phase 3 trials. Ironically, this will occur at a time when healthcare costs are rising at a rate that may not be sustainable.
Focusing on potential efficacy and safety, whether it is time to conduct phase 3 trials of sex hormones in MS is a question too broad to answer. Some sex hormones should be tested and some shouldn't. It depends on which sex hormone, which patient population, the primary outcome measure, and the safety profile. Sex hormones such as estriol, estradiol, progesterone, and testosterone are each extremely different from each other. They bind to different receptors, with different affinities, and have different mechanisms of action and safety profiles. Should phase 3 clinical trials be conducted of non-hormonal treatments in MS? Some should and some shouldn't, based on the same criteria.
The mechanism of action of estrogens in MS models includes both anti-inflammatory and directly neuroprotective properties, depending in large part on binding to estrogen receptor alpha (ERα) or ERβ. Binding to ERα on T lymphocytes and astrocytes reduces central nervous system (CNS) inflammation. Binding to ERβ on oligodendrocytes induces remyelination, which is further facilitated by binding to ERβ on CNS macrophages and dendritic cells for local immunomodulation. 2 This results in axonal sparing, increased synapses, and improved functional conduction. 3, 4 Estriol is the sex hormone candidate closest to a phase 3 trial. It binds ERβ, with low affinity for ERα. Two phase 2 trials have been completed and a third phase 2 trial recently reached its enrollment target (NCT 01466114). Estriol is the estrogen unique to pregnancy, with highest blood levels in the third trimester, when relapses are significantly reduced. 5 The first phase 2 estriol trial was a small (n = 10), single arm, crossover pilot trial with the biomarker of enhancing lesions as the primary outcome measure. Estriol treatment reduced enhancing lesions by over 70% on monthly magnetic resonance imaging (MRI). Enhancing lesions went back up when treatment was stopped and went back down again when treatment was restarted. 6 The next phase 2 trial used estriol versus placebo treatment, each in combination with glatiramer acetate (n = 158). 7 Unusual for a phase 2 trial in MS, it had reduction in clinical relapse rate as its primary outcome measure, so was powered at p = 0.1, instead of a biomarker with power at p = 0.05. Estriol as compared to placebo treatment reduced annualized relapse rates over the full 24-month duration as designed. As an exploratory outcome, 7,8 estriol as compared to placebo treatment improved cognitive performance in patients with cognitive disability at baseline. Cognitive improvement directly correlated with higher estriol blood levels. Poor compliance and decreased estriol blood levels at end of trial (month 24) coincided with loss of improvement in cognitive performance at this single time point. As the next step toward phase 3, all published results 7 were validated through third-party analysis by a contract research organization, Quintiles Inc., in fall of 2017. For context, beneficial effects of estriol and ERβ ligand treatment on cognitive performance have been shown in preclinical models of MS and several other diseases. 3, 4, 9 A treatment to improve cognition in MS would address an unmet need. Finally, estriol has an excellent safety profile in three phase 2 MS trials and from post-marketing experience in menopausal healthy women, thought due to its preferential binding to ERβ over ERα. 7 This acceptable risk:benefit ratio in many healthy women underscores estriol's safety profile when compared to some of the other anti-inflammatory disease-modifying therapies (DMTs) currently on the market for MS.
Other pregnancy factors increased in the third trimester are estradiol and progesterone. High doses of estradiol to mimic pregnancy's third trimester blood levels would not be tolerated given its high affinity for ERα in breast and uterus. A placebo-controlled phase 2 trial of lower estradiol doses in oral contraceptives (40 or 20 mg ethinylestradiol plus desogestrel) given in combination with interferon-beta-1a for 96 weeks showed no effect on relapse rate or overall disability (n = 150). 10 In exploratory outcomes, the 40 mg dose, but not the 20 mg dose, reduced cumulative active inflammatory lesions and improved cognitive performance. These results reinforce the importance of estrogen type and dose. A phase 2, placebo-controlled trial of progesterone treatment to prevent post-partum relapses 11 was stopped due to futility. Progesterone does not have potent antiinflammatory properties, but facilitates myelination. Thus, a pilot trial of progesterone with a remyelination biomarker as the primary outcome would seem more aligned with mechanism than relapse reduction.
The female-to-male ratio in MS is approximately 3:1, and testosterone treatment is protective in MS models. 3, 12 Testosterone levels are in the low normal range in MS men. Those with the lowest levels have worse disability scores. 13 A small (n = 10), single arm, crossover pilot trial showed that testosterone treatment of MS men slowed gray matter atrophy during 1 year of treatment compared to pretreatment. 14 While a phase 3 trial of testosterone treatment in MS men is premature, a phase 2 placebo-controlled trial is warranted.
In summary, phase 3 trials of select sex hormone treatments are needed since they may represent a cost-effective, safe, alternative treatment for MS, particularly given their potential for neuroprotection.
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Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS). It is the leading cause of non-traumatic neurologic disability among young adults, with an estimated prevalence of at least 500,000 people in the United States. It is a disease with distinct hormonal influences, both in female-predominant susceptibility and in gender and hormonal status-dependent variability of clinical activity and progression. Observational studies of exogenous oral contraceptives in humans historically suggested either a neutral or a possible therapeutic effect. This helps explain the renewed interest in sex hormones as potential MS treatments.
However, not every factor that may play a role in disease predisposition and course can easily become a therapeutic target. There are significant concerns to be addressed, before sex hormones can enter the mainstay of MS therapeutics. These include limited preliminary clinical data on efficacy, insufficient number of exposed patients, and a significant potential for life-altering or life-shortening side effects such as carcinogenesis, thrombogensis, and changes in reproductive behavior and plan, with the expected long-term use of these agents.
The data on estriol as disease modifying treatment (DMT) have been inconsistent, and the patient years of exposure to these therapeutics have been low. To date, there are two early phase clinical trials of estriol treatments in patients with relapsing-remitting MS (RRMS) and one phase 2 study on combined treatment with oral contraceptives as an add-on to platform therapy. [1] [2] [3] A randomized, double blind, placebo-controlled phase 2 RRMS trial has recently been completed and published. 2 Total number of patients randomized to 8 mg of daily estrogen for 24 months was 83 of 164 subjects. They also received daily norethindrone 0.7 mg for 2 weeks out of every 3 months and a platform injectable therapy, glatiramer acetate 20 mg daily. Overall, the clinical outcomes were mixed: there was no difference between the two groups in time to first relapse. The primary end point, annualized relapse rate (ARR) at 24 months, was 0.25 in the estriol group versus 0.37 in the placebo group (p = 0.077) with a pre-specified significance level of α = 0.1. This level was selected based on several trials in stroke, cancer, and amyotrophic lateral sclerosis (ALS) research that used lower power to detect treatment effect. Neither in early nor in late phase MS DMT trials had this statistic been used to support efficacy claims. There was no significant change in number or volume of T2 or gadolinium-enhancing lesions, or in total brain volume. While there was some beneficial effect on brain atrophy in the treated group in post hoc analysis, there was no difference in inflammatory magnetic resonance imaging (MRI) activity outcomes-a surprising result, considering prior studies, by these and other authors. 1, 3 In addition, a single-arm crossover design investigation of 10 subjects reported treatment with 8 mg of estriol and 100 mg of progesterone, daily, for 12 months. 1 Finally, a phase 2 study of daily ethinylestradiol 20 or 40 μg and desogestrel 125 μg, as add-on to interferon β-1-a SC injections was published. 3 Both studies suggested a beneficial effect on inflammatory activity by MRI, but not on clinical relapses. Significant reduction Visit SAGE journals online journals.sagepub.com/ home/msj
